Structure-Based Virtual Screening and Biochemical Evaluation for the Identification of Novel Trypanosoma brucei Aldolase Inhibitors

Author(s): Leonardo L.G. Ferreira, Rafaela S. Ferreira, David L. Palomino, Adriano D. Andricopulo*.

Journal Name: Current Topics in Medicinal Chemistry

Volume 18 , Issue 5 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Introduction: The glycolytic enzyme fructose-1,6-bisphosphate aldolase is a validated molecular target in human African trypanosomiasis (HAT) drug discovery, a neglected tropical disease (NTD) caused by the protozoan Trypanosoma brucei. Herein, a structure-based virtual screening (SBVS) approach to the identification of novel T. brucei aldolase inhibitors is described. Distinct molecular docking algorithms were used to screen more than 500,000 compounds against the X-ray structure of the enzyme. This SBVS strategy led to the selection of a series of molecules which were evaluated for their activity on recombinant T. brucei aldolase. The effort led to the discovery of structurally new ligands able to inhibit the catalytic activity of the enzyme.

Results: The predicted binding conformations were additionally investigated in molecular dynamics simulations, which provided useful insights into the enzyme-inhibitor intermolecular interactions.

Conclusion: The molecular modeling results along with the enzyme inhibition data generated practical knowledge to be explored in further structure-based drug design efforts in HAT drug discovery.

Keywords: Sleeping sickness, Human African trypanosomiasis, Drug discovery, Molecular docking, Molecular dynamics.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [397 - 405]
Pages: 9
DOI: 10.2174/1568026618666180427150428
Price: $65

Article Metrics

PDF: 37
PRC: 1